Navigation Links
PendoTECH Launches New In-line Single Use Conductivity Sensors for Critical Bioprocess Operations
Date:8/20/2013

PRINCETON, N.J., Aug. 20, 2013 /PRNewswire-iReach/ -- Princeton, NJ - There is an increasing trend in the biopharmaceutical manufacturing industry toward the use of disposables (e.g., flexible tubing and disposable bioprocess containers) in both clinical and commercial production to about the 1,000L process scale.  PendoTECH is launching its line of Single Use Conductivity Sensors (patent pending) to compliment the popular PendoTECH  Single Use Pressure, Temperature, UV-Absorbance Sensors that already are used in numerous bioprocess operations.  The sensors will be offered in a wide range of sizes for in-line measurement with an initial size of 1/4 inch and 1/2 inch hose barb. The conductivity sensor measurement range is 0-100mS with a readability of 0.1mS. There is built in temperature compensation provided by the embedded PendoTECH Temperature Sensor that has a range of 0-70C +/- 0.1°C.  They will easily integrate to assemblies with bags, filters, tubing, and connectors.  These disposable sensors eliminate the requirements of parts cleaning, tracking, sanitization, and possible re-sterilization of reusable measurement devices.

PendoTECH Single Use Conductivity Sensors are manufactured in an FDA Registered, ISO 13485 certified facility and each sensor is tested prior to release to ensure accuracy and to determine its unique cell constant.  All polymeric materials in the product fluid path meet USP Class VI requirements and the sensors arrive to the customer ready to use and with a certificate of quality.  They have been qualified for compatibility with gamma sterilization up to 50 KGys.

The sensors connect via a 10 foot re-usable cable to the PendoTECH Conductivity Monitor. The monitor provides for the temperature compensation which normalizes the conductivity value to 25C°. The monitor can input up to two sensors for display and has
'/>"/>

SOURCE PendoTECH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Growth Fuels Expansion As PendoTECH Relocates New Jersey Headquarters
2. PendoTECH Single Use Process Sensors Reduce The Environmental Impact Of Critical Bioprocess Operations
3. Numotion Launches New Company Website
4. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
5. Cepheid Launches Mobile Community for Ride Against TB Campaign to Benefit the American Lung Association
6. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
7. PennWell Launches New Event on Bringing Biophotonics to Market
8. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
9. CVS Caremarks Accordant Health Services Launches New Member-Focused Web Site
10. MO BIO Laboratories, Inc. launches a new kit for isolation of viral nucleic acids from environmental samples
11. Covance Launches Managed Markets Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 WuXi PharmaTech (Cayman) ... and technology platform company serving the pharmaceutical, ... small-molecule process development and manufacturing subsidiary Shanghai ... first approval from the Japan PMDA for ... a branded commercial drug in July. STA ...
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... 27, 2015 The global ... USD 3.96 billion by 2022, according to a new ... chronic venous disorders such as deep vein thrombosis, leg ... as the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) ... are also expected to boost market growth over the ...
Breaking Medicine Technology:WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... 4, 2011 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2011 third quarter financial results. ... over the internet on Tuesday, May 10, 2011 at 9:30 ... accessed by visiting the Company,s website at www.pro-dex.com . ...
... 4, 2011 Cardiogenesis Corporation (OTCQB: CGCP), a leading developer ... artery disease, today reported financial results for its first quarter ... quarter of 2011 was $3,053,000, a 6% decrease from prior ... net loss of $433,000, or $0.01 per basic and diluted ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast 2Cardiogenesis Reports First Quarter 2011 Results 2Cardiogenesis Reports First Quarter 2011 Results 3Cardiogenesis Reports First Quarter 2011 Results 4Cardiogenesis Reports First Quarter 2011 Results 5Cardiogenesis Reports First Quarter 2011 Results 6
(Date:8/27/2015)... , ... August 27, 2015 , ... According to an ... Conference on Abdominal Wall Hernia Surgery involved many conversations between hernia experts surrounding the ... there, the article notes that many different experts have different ideas about which is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, ... second year as sponsor of the “Music With A Mission” benefit concert. For the ... music education programs in the underfunded school districts of Mendon and neighboring town, Quincy, ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: